162 related articles for article (PubMed ID: 3534798)
1. Aztreonam.
Childs SJ; Bodey GP
Pharmacotherapy; 1986; 6(4):138-52. PubMed ID: 3534798
[TBL] [Abstract][Full Text] [Related]
2. Aztreonam: the first monobactam.
Neu HC
Med Clin North Am; 1988 May; 72(3):555-66. PubMed ID: 3280906
[TBL] [Abstract][Full Text] [Related]
3. Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Brogden RN; Heel RC
Drugs; 1986 Feb; 31(2):96-130. PubMed ID: 3512234
[TBL] [Abstract][Full Text] [Related]
4. Current state of infectious diseases--potential areas of directed therapy with aztreonam.
Neu HC
Am J Med; 1985 Feb; 78(2A):77-80. PubMed ID: 4038580
[TBL] [Abstract][Full Text] [Related]
5. Aztreonam.
Tunkel AR; Scheld WM
Infect Control Hosp Epidemiol; 1990 Sep; 11(9):486-94. PubMed ID: 2230052
[TBL] [Abstract][Full Text] [Related]
6. Aztreonam: the first monobactam.
Sykes RB; Bonner DP
Am J Med; 1985 Feb; 78(2A):2-10. PubMed ID: 3871589
[TBL] [Abstract][Full Text] [Related]
7. Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa.
Scully BE; Neu HC
Am J Med; 1985 Feb; 78(2):251-61. PubMed ID: 4038574
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial activity, pharmacokinetics, therapeutic indications and adverse reactions of ceftazidime.
Gentry LO
Pharmacotherapy; 1985; 5(5):254-67. PubMed ID: 3906585
[TBL] [Abstract][Full Text] [Related]
9. Aztreonam: worldwide overview of the treatment of patients with gram-negative infections.
Henry SA; Bendush CB
Am J Med; 1985 Feb; 78(2A):57-64. PubMed ID: 3881950
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience with aztreonam in four Mediterranean countries.
Daikos GK
Rev Infect Dis; 1985; 7 Suppl 4():S831-5. PubMed ID: 2934787
[TBL] [Abstract][Full Text] [Related]
11. The clinical use of aztreonam.
Schönwald S; Schoss-Vidensek Z; Car V; Krznar B
Chemotherapy; 1989; 35 Suppl 1():45-8. PubMed ID: 2731450
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of low-dose aztreonam in the treatment of moderate to severe infections due to gram-negative bacilli.
Clergeot A; Steru D; Rosset MA; Carbon C
Rev Infect Dis; 1991; 13 Suppl 7():S648-51. PubMed ID: 2068476
[TBL] [Abstract][Full Text] [Related]
13. How and why aztreonam works.
Rittenbury MS
Surg Gynecol Obstet; 1990; 171 Suppl():19-23. PubMed ID: 2244291
[TBL] [Abstract][Full Text] [Related]
14. Aztreonam activity, pharmacology, and clinical uses.
Neu HC
Am J Med; 1990 Mar; 88(3C):2S-6S; discussion 38S-42S. PubMed ID: 2180293
[TBL] [Abstract][Full Text] [Related]
15. Aztreonam.
Clark P
Obstet Gynecol Clin North Am; 1992 Sep; 19(3):519-28. PubMed ID: 1436929
[TBL] [Abstract][Full Text] [Related]
16. Carbapenems and monobactams: imipenem, meropenem, and aztreonam.
Hellinger WC; Brewer NS
Mayo Clin Proc; 1999 Apr; 74(4):420-34. PubMed ID: 10221472
[TBL] [Abstract][Full Text] [Related]
17. Clinical experience with aztreonam.
Stutman HR
Pediatr Infect Dis J; 1989 Sep; 8(9 Suppl):S109-12; discussion S128-32. PubMed ID: 2682508
[TBL] [Abstract][Full Text] [Related]
18. Aztreonam, a new monobactam antimicrobial.
Guay DR; Koskoletos C
Clin Pharm; 1985; 4(5):516-26. PubMed ID: 3902330
[TBL] [Abstract][Full Text] [Related]
19. The role of aztreonam in treatment of complicated urinary tract infections in children.
Kline MW
Pediatr Infect Dis J; 1989 Sep; 8(9 Suppl):S113-6; discussion S128-32. PubMed ID: 2682509
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacology of aztreonam in healthy recipients and patients: a review.
Swabb EA
Rev Infect Dis; 1985; 7 Suppl 4():S605-12. PubMed ID: 3909317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
